No evidence for decay of the latent reservoir in HIV-1-infected patients receiving intensive enfuvirtidecontaining antiretroviral therapy

Rajesh T. Gandhi, Ronald J. Bosch, Evgenia Aga, Mary Albrecht, Lisa M. Demeter, Carrie Dykes, Barbara Bastow, Michael Para, Jun Lai, Robert F. Siliciano, Janet D. Siliciano, Joseph J. Eron

Research output: Contribution to journalArticle

Abstract

Human immunodeficiency virus type 1 (HIV-1) persists in a latent reservoir of infected resting memory CD4 cells in patients receiving antiretroviral therapy. We assessed whether multitarget therapy with enfuvirtide, 2 reverse-transcriptase inhibitors, and a ritonavir-boosted protease inhibitor leads to decay of this reservoir. Nineteen treatment-naive patients initiated this regimen; 9 experienced virologie suppression and continued enfuvirtide-containing therapy for at least 48 weeks. In enfuvirtide-treated patients with virological suppression, there was no decay of the latent reservoir (95% confidence interval for half-life, 11 months to infinity). The stability of the latent reservoir despite intensive therapy suggests that new strategies are needed to eradicate HIV-1 from this reservoir. (ClinicalTrials.gov identifier: NCT00051831.)

Original languageEnglish (US)
Pages (from-to)293-296
Number of pages4
JournalJournal of Infectious Diseases
Volume201
Issue number2
DOIs
StatePublished - Jan 15 2010

    Fingerprint

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Cite this